Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyPremera Bluecross Omalizumab Coverage Update | Ope…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.513

    Omalizumab Products

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.513 alerts

    Get alerted when Policy 5.01.513 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical and pharmacy benefit coverage and site-of-service medical necessity criteria for omalizumab products (Xolair and Omlyclo) for indications including moderate to severe persistent asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy; intended for providers and utilization review.

    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab Products
    Policy CodePolicy 5.01.513
    Change TypeMaterial clinical and operational updates
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, required prior therapies, baseline total serum IgE and body weight; initial approvals will be issued for 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    Updated initial authorization length for all reviews from 6 months to 12 months and removed reference to non-formulary exception reviews.

    Added Exdensur (depemokimab-ulaa) to the list of medications not to be used concurrently with omalizumab for the treatment of asthma.

    Updated chronic idiopathic urticaria dose limit to 600 mg every 2 weeks.

    Updated asthma criteria to use maximum tolerated doses of inhaled corticosteroid rather than maximum doses and added FEV1/FVC < 0.80 as an option.

    Updated CRSwNP criteria to require bilateral disease confirmed by exam, CT, or endoscopy and prior use of systemic corticosteroids in last 2 years or prior bilateral polyp surgery or contraindication to systemic steroids.

    Clarified that medications listed are subject to the product's FDA dosage and administration prescribing information and that non-formulary exception authorizations may be approved up to 12 months.

    Updated initial approval length for Xolair for chronic idiopathic urticaria to 6 months (historical change noted in 2023) then generalized initial authorization update to 12 months in 2026 update.

    Initial authorization period for all reviews changed from 6 months to 12 months.

    Added Exdensur (depemokimab-ulaa) to the list of medications that should not be used concurrently with omalizumab when treating asthma.

    Chronic idiopathic urticaria dose limit updated to 600 mg every 2 weeks.

    Policy title updated from "Xolair (omalizumab)" to "Omalizumab Products" and Omlyclo (omalizumab-igec) was added with the same criteria as Xolair.

    Site of service medical necessity review can apply to injection drugs.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsnew initial authorization period for reviews
    600 mg q2wCIU dose limit
    ≥3 in-officeinitial administration requirement
    tezepelumab, dupilumab, depemokimabconcurrent use exclusions include
    J2357, Q5154HCPCS codes

    Coverage Criteria and Indications

    Moderate to severe persistent asthma (omlyclo/Xolair)

    Covered when ALL of the following are met

    Asthma indication criteria: Moderate to severe persistent asthma with positive skin test or in vitro reactivity to a perennial aeroallergen; age ≥6 years; using maximum tolerated doses of an inhaled corticosteroid; using an inhaled long-acting beta-agonist (LABA); and meets at least one asthma severity marker (2 or more oral corticosteroid-requiring exacerbations in the previous 12 months OR 1 or more exacerbations requiring hospitalization/ED/urgent care in the previous 12 months OR FEV1 <80% predicted OR FEV1/FVC <0.80 OR asthma worsens on tapering of oral corticosteroid therapy).
    Laboratory and weight criteria: Total serum IgE between 30–1,300 IU/mL for ages 6–12 OR 30–700 IU/mL for age ≥12 years; positive skin test or RAST to a perennial aeroallergen; body weight between 20 kg and 150 kg; dosing limited to 750 mg every 4 weeks per dosing table for applicable IgE/weight strata.
    Concomitant therapy and prescriber: Not used in combination with specified biologics when those medications are being used for asthma (Cinqair/reslizumab, Dupixent/dupilumab, Exdensur/depemokimab-ulaa, Fasenra/benralizumab, Nucala/mepolizumab, Tezspire/tezepelumab); medication prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
    Dosing determination and documentation: Dose and frequency for asthma are determined by baseline total serum IgE and body weight using the manufacturer dosing tables; document pre-treatment IgE and body weight; do not use on-treatment IgE for dose changes; retest IgE only if treatment interruption ≥1 year.

    Severe chronic idiopathic urticaria (Xolair/Omlyclo)

    Covered when ALL of the following are met

    Urticaria criteria: Age ≥12 years; no evidence of an alternate cause; at least 6 weeks of symptoms (chronic urticaria, itching, hives, or angioedema); failed to respond to or intolerant of at least 2 H1-antihistamines at high doses (≥2x up to 4x usual dosing) or maximum tolerated dose; plans to continue low-dose H1 antihistamines.
    Prescriber and combination therapy: Medication prescribed by or in consultation with an allergist, immunologist, pulmonologist or dermatologist; not used in combination with Dupixent (dupilumab) or Rhapsido (remibrutinib) for chronic urticaria; dose limited to 600 mg every 2 weeks (per 2026 update).
    CIU dosing and monitoring: Administer omalizumab per CIU dosing guidance; reassess need for continued therapy periodically; initial authorization duration follows policy standards (initial approvals issued for 12 months).

    Chronic rhinosinusitis with nasal polyps (CRSwNP)

    Covered when ALL of the following are met

    CRSwNP patient criteria: Age ≥18 years; inadequately controlled bilateral CRSwNP confirmed by physical exam, sinus CT, or nasal endoscopy; pretreatment total serum IgE ≥30 IU/mL; weight between 30 kg and 150 kg; has at least 2 of the following symptoms: facial pressure/pain, moderate–severe nasal congestion/discharge/obstruction, or significant loss of smell.
    Prior therapy and concomitant use: Inadequate response or intolerance to intranasal corticosteroid monotherapy; medication prescribed in combination with an intranasal corticosteroid; AND one of: prior systemic corticosteroid treatment for nasal polyps within the last 2 years OR contraindication to systemic corticosteroids OR prior bilateral nasal polyp surgery.
    Prescriber and combination therapy: Prescribed by or in consultation with an allergist, immunologist, or otolaryngologist; not used in combination with dupilumab, mepolizumab, or tezepelumab for CRSwNP; dose limited to 600 mg every 2 weeks based on serum IgE and weight dosing table.

    IgE-mediated food allergy

    Covered when ALL of the following are met

    Food allergy diagnosis and age: Age ≥1 year; diagnosed IgE-mediated food allergy evidenced by signs and symptoms of a significant systemic allergic reaction within a short period after known ingestion AND a positive skin prick test or positive serum-specific IgE to one or more foods.
    Concomitant management and exclusions: Medication used in conjunction with allergen avoidance diet; patient prescribed an epinephrine auto-injector; medication not used concomitantly with Palforzia (peanut allergen powder); dosing per serum IgE and weight tables as applicable.
    Prescriber: Medication prescribed by or in consultation with an allergist or immunologist; at least three doses administered in a healthcare provider's office prior to consideration of self-administration.

    General coverage criteria

    Covered when clinical criteria consistent with approved indications and benefit management are met:

    Indication and prior therapy: Patient has one of the supported indications (asthma, chronic idiopathic urticaria, CRSwNP, or selected IgE-mediated food allergy) AND documentation of prior appropriate controller therapy and inadequate control or persistent symptoms despite those therapies; therapy is positioned as an additional/last-line option.
    Administration requirement: At least three doses must be administered in a healthcare provider's office before consideration of self-administration; provider documents assessment of anaphylaxis risk and mitigation strategies.≥3 in-office doses
    Evidence of benefit by indication: For each indication, clinical trial entry criteria and demonstrated benefit should be met (e.g., asthma: reduced exacerbations; CIU: UAS7 ≥16 and inadequate response to H1 antihistamines; CRSwNP: NPS and NCS trial criteria; food allergy: OUtMATCH trial entry criteria).

    Covered indications with criteria

    Covered when policy-specified diagnostic confirmation, prior therapies, dosing limits, and non-concurrent-biologic rules are met.

    Asthma - moderate to severe: Meets updated definition of moderate to severe persistent asthma (e.g., ≥2 oral corticosteroid-requiring exacerbations in prior 12 months OR ≥1 exacerbation requiring hospitalization/ED/urgent care in prior 12 months OR FEV1 <80% predicted OR dependence on systemic corticosteroids or asthma worsens on taper); on maximally tolerated inhaled corticosteroid therapy; dosing follows FDA label; not used concurrently with specified biologics (e.g., tezepelumab, dupilumab for certain indications, depemokimab).
    Chronic rhinosinusitis with nasal polyps (CRSwNP): Inadequately controlled bilateral CRSwNP confirmed by exam, sinus CT, or nasal endoscopy; has two or more key symptoms; prior systemic corticosteroid use for polyps in last 2 years OR contraindication to systemic steroids OR prior bilateral polyp surgery; dosing per FDA label; concurrent use with dupilumab for nasal polyps not permitted.
    Chronic idiopathic/spontaneous urticaria (CIU/CSU): Patient ≥12 years with CIU refractory to H1-antihistamines; dosing limited to maximum 600 mg every 2 weeks per 2026 update; initial authorization lengths standardized to 12 months.600 mg every 2 weeks

    Coverage criteria and dosing rules

    Coverage and dosing are guided by indication-specific rules and manufacturer dosing tables; key conditions include:

    Authorization conditions (general): Initial authorization duration = 12 months; dosing must follow product dosing tables based on pre-treatment total serum IgE and body weight; document baseline IgE and weight; adjust dose for significant weight changes; do not use on-treatment IgE to guide dosing; re-test IgE if treatment interruption ≥1 year.
    Asthma-specific concurrent therapy restriction: Do not use omalizumab concurrently with Exdensur (depemokimab-ulaa) when treating asthma; concurrent use with other listed biologics may trigger denial.
    Chronic idiopathic/spontaneous urticaria dosing limit: Dose limit for chronic idiopathic urticaria updated to a maximum of 600 mg every 2 weeks (per 2026 update) and will be enforced in authorization decisions.600 mg every 2 weeks

    Asthma — Dosing and Dose Determination

    Covered for moderate to severe persistent asthma when ALL applicable criteria are met per the policy (criteria detailed elsewhere in the policy).

    Asthma dosing and dose determination: For asthma, administer omalizumab every 2 weeks (or as appropriate per dosing table); the exact mg dose and frequency are determined by baseline total serum IgE and body weight using the manufacturer dosing tables; do not re-test IgE during treatment to guide dosing; if treatment interrupted ≥1 year, re-test IgE to determine dosing; adjust doses for significant weight changes.

    Chronic Idiopathic Urticaria — Dosing

    Covered for chronic idiopathic urticaria when ALL applicable criteria are met.

    CIU dosing: Administer omalizumab 150 mg or 300 mg subcutaneously every 4 weeks for chronic idiopathic urticaria; CIU dosing is not dependent on serum IgE or body weight; periodically reassess need for continued therapy; note policy enforces a maximum allowable dosing frequency/amount for CIU of 600 mg every 2 weeks per 2026 update.
    CIU prior authorization and duration: Initial authorizations follow policy standard initial authorization duration (12 months); document prior antihistamine trials and UAS7 or equivalent symptom documentation as required.

    The following uses are identified as investigational or unapproved and are not covered under this policy: allergic rhinitis, atopic dermatitis, other IgE‑mediated allergic conditions not specifically listed in the policy, latex allergy, bullous pemphigoid, and other uses not specified in the approved indications.

    Clinical trial evidence did not demonstrate consistent efficacy for the 75 mg dose in chronic idiopathic urticaria; the 75 mg dose is not approved for that indication and therefore is not an acceptable dosing option for CIU.

    Concurrent administration of omalizumab with other biologic therapies for the same indication is restricted. Recent updates explicitly add Exdensur (depemokimab‑ulaa) to biologics not to be used concurrently for asthma and reiterate that agents such as Tezspire (tezepelumab) and Dupixent (dupilumab) are not to be combined with omalizumab when used for overlapping indications; such concurrent use may trigger denial of medical necessity.

    The dosing tables include specific cells where combinations of very high pre‑treatment total serum IgE and patient body weight are listed as DO NOT DOSE. Entries labeled DO NOT DOSE indicate that a recommended omalizumab dose is not provided for those IgE/weight strata and such combinations are not supported by the dosing guidance.

    The policy states that omalizumab should not be used in combination with certain other biologics for the same treated condition. Examples called out in updates include dupilumab, tezepelumab, mepolizumab, and depemokimab (Exdensur). Combination use with these agents for asthma, CRSwNP, or urticaria is restricted and may be considered not medically necessary.

    Site‑of‑service medical necessity criteria apply to omalizumab administration. Infusion or injection at higher‑cost or less appropriate locations may be considered not medically necessary when site‑of‑service criteria are not met. The policy also specifies that initial administration settings (including review of site‑of‑service) can be applied to injection drugs such as omalizumab.

    Requests for omalizumab that do not document required diagnostic confirmation or prior therapy trials will not meet medical necessity. Examples include CRSwNP without confirmation by physical exam, sinus CT, or nasal endoscopy or without prior systemic corticosteroid use in the past 2 years (or prior bilateral polyp surgery or a contraindication), and CIU without documented failure/intolerance to the required antihistamine trials.

    Cells in the asthma dosing table marked DO NOT DOSE reflect that no dosing recommendation is provided for those high pre‑treatment total serum IgE and weight combinations; such entries indicate the dose cannot be determined from the table and imply the agent should not be dosed for those parameter combinations.

    The policy explicitly lists multiple biologics that should not be used concurrently with omalizumab for overlapping indications. For asthma and CRSwNP this includes agents such as Tezspire (tezepelumab), Dupixent (dupilumab), and the newly added Exdensur (depemokimab‑ulaa). Concurrent combination therapy with these specified biologics is considered not medically necessary.

    Billing and Coding

    HCPCS codesHCPCS
    J2357Injection, omalizumab (Xolair), 5 mg.
    Q5154Injection, omalizumab-igec (Omlyclo), biosimilar, 5 mg (new code effective 10/01/25).
    HCPCS codes for XolairHCPCSCovered
    J2357Omalizumab (Xolair) injection
    inv-21: Serum total IgE
    Required minimumTotal serum IgE ≥ 30 IU/mL for applicable indications
    Upper limits by ageAges 6–12: up to 1,300 IU/mL; Age ≥12: up to 700 IU/mL
    Use for dosingPre-treatment (baseline) total serum IgE is used with body weight to determine dose per dosing tables
    On-treatment testingDo not use on‑treatment IgE to guide dosing because levels are elevated during therapy
    inv-22: Weight
    Asthma weight range20 kg to 150 kg (44–330 lbs) for asthma dosing

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; bill with J2357 or Q5154

    Prior authorization is required for omalizumab products; bill using HCPCS J2357 for omalizumab (Xolair) and Q5154 for omalizumab-igec (Omlyclo).

    • J2357 — Injection, omalizumab (Xolair), 5 mg
    • Q5154 — Injection, omalizumab-igec (Omlyclo), biosimilar, 5 mg (effective 10/01/25)
    Prior Authorization

    Managed via pharmacy and medical benefits; PA required

    Omalizumab is managed through both the pharmacy and medical benefits and requires prior authorization consistent with benefit management.

    Prior Authorization

    Prior authorization required; initial approval length standardized

    Background and Clinical Evidence

    Omalizumab is a monoclonal antibody that binds circulating IgE and prevents IgE binding to high‑affinity FcεRI receptors on mast cells and basophils, reducing allergic mediator release. It is indicated for selected patients with moderate to severe persistent allergic asthma, chronic idiopathic urticaria refractory to antihistamines, inadequately controlled chronic rhinosinusitis with nasal polyps, and for selected IgE‑mediated food allergy management when used with allergen avoidance. The policy covers Xolair and the biosimilar Omlyclo under the same clinical criteria and includes direction on dosing determination, prior therapy requirements, site‑of‑service review, and documentation needed to support medical necessity.

    inv-48: IgE-mediated food allergy definition
    DefinitionIgE‑mediated food allergy: clinical signs of a systemic allergic reaction after ingestion of a known food plus a positive skin prick test or positive serum‑specific IgE to one or more foods
    Age thresholdPolicy supports treatment for individuals aged ≥1 year with IgE‑mediated food allergy
    Concomitant managementTreatment must be used in conjunction with an allergen‑avoidance diet and patient should have an epinephrine auto‑injector prescribed

    Policy Revision History

    2026-08-01Effective dateLatest

    Policy updated: initial authorizations for all reviews changed from 6 months to 12 months; Exdensur (depemokimab-ulaa) added to asthma concurrent-use exclusions; chronic idiopathic urticaria dose limit set to 600 mg every 2 weeks.

    2026-07-14Revision approval

    Policy title changed to 'Omalizumab Products' and Omlyclo (omalizumab-igec) was added to the policy with the same criteria as Xolair; site-of-service review added for Omlyclo.

    2026-01-13
    Policy Summary
    PayerPremera Bluecross
    PolicyOmalizumab Products
    Policy CodePolicy 5.01.513
    Change TypeMaterial clinical and operational updates
    Effective DateAug 1, 2026
    Last ReviewJul 14, 2026
    Next Review DateJul 14, 2026
    Key ActionSubmit prior authorization with documentation of diagnosis, required prior therapies, baseline total serum IgE and body weight; initial approvals will be issued for 12 months.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsBilling and CodingProvider Actions, Prior Authorization, and DocumentationBackground and Clinical EvidencePolicy Revision History
    CRSwNP weight range
    30 kg to 150 kg (66–330 lbs) for CRSwNP dosing
    Dose adjustmentsDoses should be adjusted for significant changes in body weight per dosing tables
    inv-23: Initial authorization length
    Initial authorization periodInitial authorizations will be issued for 12 months for all reviews
    Historical notePreviously initial approvals (for some reviews) were 6 months; updated to 12 months in 2026
    Application12‑month initial authorization applies across indications and review types per policy update
    inv-24: CIU dosing limit
    Maximum CIU dosing frequencyDose limit for chronic idiopathic urticaria set to a maximum of 600 mg every 2 weeks
    Standard CIU dosing (label)Typical CIU dosing per label: 150 mg or 300 mg every 4 weeks (dosing not weight- or IgE‑dependent)
    Enforcement600 mg q2w limit enforced in authorization decisions per 2026 update
    inv-25: Pre-treatment total serum IgE and body weight
    Baseline data requiredDocument pre-treatment (baseline) total serum IgE and body weight used for initial dose determination
    Re-testing rule after interruptionIf treatment interrupted <1 year: use original baseline IgE for re-dosing; if interrupted ≥1 year: re-test total serum IgE for dose determination
    On-treatment IgE limitationTotal IgE levels are elevated during treatment and remain elevated up to one year after discontinuation; do not use on‑treatment IgE to guide dosing
    inv-26: Asthma dosing table thresholds
    Dose determination methodAsthma dosing amount and frequency are determined by baseline total serum IgE range and body weight per the policy dosing tables
    Administration frequencyAsthma dosing commonly administered every 2 weeks (some cells/strata use every 4 weeks per table)
    'DO NOT DOSE' entriesDosing tables include 'DO NOT DOSE' cells for very high IgE/weight combinations where dosing is not provided

    Prior authorization is required and initial approvals are standardized to a 12-month authorization period for all reviews.

    Prior Authorization

    Authorization duration — 12 months

    Initial authorizations will be issued for 12 months for all reviews.

    Prior Authorization

    12-month PA with possible site-of-service review

    Prior authorization approvals are issued for an initial 12-month period; site-of-service medical necessity review may be applied to injection drugs including Omlyclo/Xolair.

    Documentation Required

    Confirm prior/concomitant therapies by indication

    Document that required prior or concomitant therapies were used per indication: asthma patients must be on appropriate inhaled controller therapy; CIU patients must have failed antihistamines; CRSwNP must have tried intranasal corticosteroid monotherapy.

    • Asthma: using maximum tolerated inhaled corticosteroid and an inhaled LABA
    • CIU: failed or intolerant to ≥2 H1-antihistamines at high doses or max tolerated dose
    • CRSwNP: inadequate response or intolerance to intranasal corticosteroid monotherapy
    Step Therapy

    Therapy sequencing — document failed controller therapy

    Omalizumab is positioned as an add-on/last-line therapy; document trials of appropriate inhaled corticosteroid and controller agents prior to approval.

    • Provide medication history showing inadequate control despite inhaled corticosteroid and other controller therapy
    Step Therapy

    CRSwNP — prior systemic steroid use or surgery required

    For CRSwNP, document prior systemic corticosteroid use within the last 2 years, or contraindication to systemic steroids, or prior bilateral nasal polyp surgery before approval.

    • Evidence of systemic corticosteroid treatment for polyps in the last 2 years OR
    • Contraindication to systemic corticosteroids OR
    • Previous bilateral nasal polyp surgery
    Note

    Background medication classes — reference appendix

    Refer to the appendix for background medication classes used as supportive therapy (inhaled corticosteroids, long-acting bronchodilators, leukotriene modifiers, H1 antihistamines).

    • Inhaled corticosteroids (e.g., fluticasone, budesonide, mometasone)
    • Long-acting bronchodilators (e.g., salmeterol)
    • Leukotriene modifiers (e.g., montelukast)
    • H1 antihistamines (e.g., cetirizine, fexofenadine)
    Step Therapy

    Prior medication/step requirements must be documented

    Policy includes prior medication/step requirements for indications such as CIU and CRSwNP; ensure documentation of prior medication trials (e.g., ≥2 H1-antihistamines for CIU; intranasal steroid for CRSwNP).

    • CIU: failure of ≥2 H1-antihistamines at high doses
    • CRSwNP: inadequate response to intranasal corticosteroid monotherapy or prior systemic steroid/surgery
    Documentation Required

    Submit full medical records showing diagnosis and medication history

    Submit medical records documenting diagnosis, relevant history, physical evaluation, and complete medication history to demonstrate that medical necessity criteria are met.

    • Office visit notes with diagnosis and relevant history
    • Physical examination findings
    • Medication history including prior controllers and antihistamines
    Documentation Required

    Document ≥3 in-office doses and anaphylaxis assessment before self-administration

    When initiating therapy or considering self-administration, document the administration setting and confirm that at least three doses were administered in a healthcare provider's office and that anaphylaxis risk was assessed.

    • Record location of each administration and that ≥3 in-office doses were given
    • Document assessment of anaphylaxis risk and mitigation strategies prior to self-administration
    Documentation Required

    Include indication-specific supporting documentation

    Provide supporting documentation specific to the indication (e.g., for CRSwNP: confirm bilateral disease by physical exam, sinus CT, or nasal endoscopy; for asthma, document positive skin test/RAST and exacerbation history).

    • CRSwNP: physical exam, sinus CT, or nasal endoscopy confirming bilateral polyps
    • Asthma: positive skin test or RAST to a perennial aeroallergen and exacerbation history
    Documentation Required

    Document baseline total serum IgE and weight for dosing

    Document pre-treatment total serum IgE and body weight used for dose determination; note that on-treatment IgE should not be used to guide dosing and re-testing is allowed only if treatment interruption ≥1 year.

    • Record baseline total serum IgE value used for initial dosing
    • Record body weight at baseline and for dose adjustments
    • If treatment interrupted <1 year, use original baseline IgE for re-dosing; re-test if interruption ≥1 year
    Documentation Required

    Record dosing basis, weight, and CIU symptom duration/reassessment

    For dosing determinations and for chronic idiopathic urticaria, record the prior dosing determination (initial serum IgE used if interruption <1 year), body weight for adjustments, and for CIU document ≥6 weeks of symptoms and periodic reassessment of ongoing need.

    • CIU: document ≥6 weeks of symptoms prior to initiation
    • Record prior dosing basis and weight for dose changes
    • Periodically reassess need for continued CIU therapy
    Denial Risk

    Site-of-service review may trigger denial if SOS criteria not met

    Site-of-service reviews may deem services not medically necessary if site-of-service criteria are not met; ensure the administration location meets policy SOS requirements (preferred sites: physician office, infusion center, home infusion, or hospital outpatient).

    • Preferred medically necessary sites include physician office, infusion center, home infusion, hospital outpatient
    • Services at nonmedically necessary sites may be denied if SOS criteria are not met
    Prior Authorization

    Require ≥3 in-office administrations before self-administration

    Before approving self-administration, confirm the patient received at least three doses in a healthcare provider's office; requests lacking this may be subject to benefit management or denial.

    • Documented record of ≥3 in-office administrations is required prior to self-administration
    Denial Risk

    Denial risk if diagnostic or prior-therapy criteria not documented

    Requests may be denied if the patient does not meet updated diagnostic or prior-therapy criteria for the requested indication (for example, CRSwNP without bilateral confirmation or without prior systemic steroid use/surgery).

    • CRSwNP: denial risk if no exam, CT, or endoscopy confirming bilateral disease
    • Denial risk when prior therapy requirements (e.g., prior systemic steroids or surgery) are not documented
    Denial Risk

    Do not approve concurrent omalizumab + Exdensur for asthma

    Concurrent use of omalizumab with Exdensur (depemokimab-ulaa) for asthma is not permitted; requests for concurrent therapy with listed agents may be denied.

    • Do not approve concurrent use of omalizumab with Exdensur for asthma
    Denial Risk

    Concurrent biologic therapy for same indication is restricted

    Do not use omalizumab concurrently with certain other biologics (e.g., Tezspire, Dupixent, Exdensur and other listed agents) for the same indication; concurrent biologic therapy requests may be denied.

    • Concurrent biologic therapy for the same indication is restricted and may trigger denial
    Note

    Background — follow indication-specific PA and documentation rules

    Omalizumab is an anti-IgE monoclonal antibody indicated for specified allergic conditions; follow indication-specific criteria and the policy's administration and documentation requirements when requesting authorization.

    • Indications include moderate to severe persistent allergic asthma, chronic idiopathic urticaria, CRSwNP, and select IgE-mediated food allergy
    • Ensure PA, documentation of prior therapies, dosing basis (IgE and weight where applicable), and SOS requirements are met
    inv-49: Site of service (SOS) definition
    DefinitionSite of service (SOS): location where the drug is administered (e.g., physician's office, infusion center, hospital outpatient infusion department, or home) and subject to medical‑necessity criteria
    Initial course considerationCertain sites are considered medically necessary for the first 90 days for initial course or re‑initiation after ≥6 months unless standard dosing interval is ≥6 months
    Review implicationSite‑of‑service medical necessity review may be applied to injection drugs and can affect coverage determination
    inv-50: Mechanism of action
    MechanismOmalizumab binds circulating IgE and prevents IgE binding to high‑affinity FcεRI receptors on mast cells and basophils, reducing release of allergic mediators and decreasing FcεRI receptor expression
    Therapeutic effectBy blocking IgE, omalizumab reduces immune cell sensitivity and decreases mediator (e.g., histamine) release that causes allergic reactions
    Clinical applicationsMechanism underpins use in allergic asthma, chronic urticaria, nasal polyps, and select IgE‑mediated food allergy indications
    inv-51: Nasal polyp score (NPS)
    Scoring scaleNasal Polyp Score (NPS): endoscopic score 0–4 per nostril (total 0–8)
    Trial inclusion thresholdCRSwNP trials required total NPS ≥5 with NPS ≥2 in each nostril despite nasal corticosteroid therapy
    UseNPS quantifies polyp burden to confirm bilateral disease and eligibility for therapy
    inv-52: UAS7
    Definition and rangeUAS7 (Weekly Urticaria Activity Score): composite score range 0–42 combining weekly itch severity (0–21) and hive count (0–21)
    Trial entry requirementCIU trials required UAS7 ≥16 and a weekly itch severity score ≥8 despite H1 antihistamine therapy
    Clinical useUAS7 used to quantify disease severity and response to therapy in CIU
    inv-53: Moderate to severe persistent asthma definition
    Core elementsModerate to severe persistent asthma: positive perennial aeroallergen test, age ≥6 years, on maximum tolerated inhaled corticosteroid and LABA, plus at least one severity marker (≥2 oral corticosteroid‑requiring exacerbations in prior 12 months OR ≥1 exacerbation requiring hospitalization/ED/urgent care OR FEV1 <80% predicted OR FEV1/FVC <0.80 OR asthma worsens on oral steroid taper)
    Laboratory and weight criteriaBaseline total serum IgE 30–1,300 IU/mL for ages 6–12 or 30–700 IU/mL for ≥12 years; weight 20–150 kg
    Concurrent biologic restrictionNot to be used concurrently with listed biologics for asthma (e.g., tezepelumab, depemokimab/Exdensur, dupilumab where indicated)
    inv-54: Total serum IgE re-testing guidance
    On‑treatment IgE limitationTotal IgE levels increase during treatment and remain elevated for up to one year after discontinuation; do not use on‑treatment IgE to guide dosing
    Re‑testing after interruptionRe-testing of total serum IgE for dose determination is permitted only if treatment has been interrupted for ≥1 year
    Baseline relianceDose determination after interruptions <1 year should use the serum IgE obtained at the initial dose determination
    inv-55: Total serum IgE levels elevated during and after treatment guidance
    Duration of elevationTotal serum IgE levels may remain elevated during treatment and for up to one year after stopping omalizumab
    Dosing implicationBecause IgE remains elevated, do not use on‑treatment IgE measurements to guide dose adjustments during ongoing therapy
    When to re-testRetest total serum IgE only if treatment interrupted for ≥1 year to re‑establish baseline for dosing tables
    Interim review

    CRSwNP criteria clarified to require bilateral disease confirmed by exam, CT, or endoscopy and prior systemic corticosteroid use within 2 years or prior bilateral polyp surgery; added non-concurrent use restriction with tezepelumab for CRSwNP.

    2025-07-01Interim review

    Asthma criteria changed from maximum dose to maximum tolerated inhaled corticosteroid and an FEV1/FVC <0.80 option was added; changed oral corticosteroid dependence language to 'worsens on taper'.

    2025-04-01Interim review

    Clarified that medications in the policy follow FDA dosing and that non-formulary exception authorizations may be approved up to 12 months.

    2025-01-27Annual review

    Updated asthma criteria and related coverage language (recorded as annual review actions in 2025 references).

    2023-01-01Annual review (2023 rationale)

    Updated definition of moderate to severe persistent asthma to include exacerbations requiring oral corticosteroids and adjusted CIU initial approval length historically to 6 months (later changed).